Results 231 to 240 of about 121,650 (304)

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy   +10 more
wiley   +1 more source

Intracellular Cyclic Adenosine 3’, 5’-Monophosphate and Relaxing Effects of Isoprenaline and Papaverine on Smooth Muscle of Intestine

open access: diamond, 1972
Issei Takayanagi   +4 more
openalex   +1 more source

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report
Carel W. le Roux   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy